Inhibition of nitric oxide synthase does not affect α2-adrenergic- mediated cerebral vasoconstriction

R. W. McPherson, Jeffrey Kirsch, R. J. Traystman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We assessed whether blocking nitric oxide (NO) synthase alters the cerebral blood flow (CBF) response to α2-adrenergic stimulation during isoflurane anesthesia in dogs. In control animals (n = 6), CBF (microspheres), cerebral oxygen consumption (CMRO2), and electro- encephalograph (EEG) were measured after 1 h of isoflurane (1.4% end-tidal) and before and 5, 10, and 20 min after injection of an α2-adrenergic receptor agonist (dexmedetomidine 10 μg/kg, intravenous [IV] bolus). Dogs in a second group (n = 6) were treated similar to control animals except that an irreversible blocker of NO synthase, N(ω)-nitro-L-arginine methyl ester (L- NAME; 40 mg/kg, IV) was administered 1 h before induction of anesthesia. In control dogs, dexmedetomidine decreased CBF by 37% (P <0.05). Blood flow remained decreased for the 20 min observation period in all brain regions except cerebellum and caudate. In the L-NAME group, control CBF was 45% less than baseline flow in the control group (P <0.05) and dexmedetomidine further decreased CBF from 41 ± 7 mL · 100 g-1 · min-1 to 24 ± 2 mL · 100 g-1 · min-1 (P <0.05). There was no difference between groups in the percent of reduction of blood flow in any region after dexmedetomidine administration. Control CMRO2 was similar in the two groups and was unchanged by dexmedetomidine. These data demonstrate that L-NAME reduces CBF and that block of NO synthase does not affect α2-adrenergic-mediated decreases in CBF during isoflurane anesthesia.

Original languageEnglish (US)
Pages (from-to)67-72
Number of pages6
JournalAnesthesia and Analgesia
Volume78
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Vasoconstriction
Dexmedetomidine
Nitric Oxide Synthase
Adrenergic Agents
Isoflurane
NG-Nitroarginine Methyl Ester
Anesthesia
Dogs
Adrenergic Agonists
Microspheres
Oxygen Consumption
Cerebellum
Observation
Control Groups
Injections

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Inhibition of nitric oxide synthase does not affect α2-adrenergic- mediated cerebral vasoconstriction. / McPherson, R. W.; Kirsch, Jeffrey; Traystman, R. J.

In: Anesthesia and Analgesia, Vol. 78, No. 1, 1994, p. 67-72.

Research output: Contribution to journalArticle

@article{a37d6d5ee0d643efbaea7f7c8e1815a0,
title = "Inhibition of nitric oxide synthase does not affect α2-adrenergic- mediated cerebral vasoconstriction",
abstract = "We assessed whether blocking nitric oxide (NO) synthase alters the cerebral blood flow (CBF) response to α2-adrenergic stimulation during isoflurane anesthesia in dogs. In control animals (n = 6), CBF (microspheres), cerebral oxygen consumption (CMRO2), and electro- encephalograph (EEG) were measured after 1 h of isoflurane (1.4{\%} end-tidal) and before and 5, 10, and 20 min after injection of an α2-adrenergic receptor agonist (dexmedetomidine 10 μg/kg, intravenous [IV] bolus). Dogs in a second group (n = 6) were treated similar to control animals except that an irreversible blocker of NO synthase, N(ω)-nitro-L-arginine methyl ester (L- NAME; 40 mg/kg, IV) was administered 1 h before induction of anesthesia. In control dogs, dexmedetomidine decreased CBF by 37{\%} (P <0.05). Blood flow remained decreased for the 20 min observation period in all brain regions except cerebellum and caudate. In the L-NAME group, control CBF was 45{\%} less than baseline flow in the control group (P <0.05) and dexmedetomidine further decreased CBF from 41 ± 7 mL · 100 g-1 · min-1 to 24 ± 2 mL · 100 g-1 · min-1 (P <0.05). There was no difference between groups in the percent of reduction of blood flow in any region after dexmedetomidine administration. Control CMRO2 was similar in the two groups and was unchanged by dexmedetomidine. These data demonstrate that L-NAME reduces CBF and that block of NO synthase does not affect α2-adrenergic-mediated decreases in CBF during isoflurane anesthesia.",
author = "McPherson, {R. W.} and Jeffrey Kirsch and Traystman, {R. J.}",
year = "1994",
language = "English (US)",
volume = "78",
pages = "67--72",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Inhibition of nitric oxide synthase does not affect α2-adrenergic- mediated cerebral vasoconstriction

AU - McPherson, R. W.

AU - Kirsch, Jeffrey

AU - Traystman, R. J.

PY - 1994

Y1 - 1994

N2 - We assessed whether blocking nitric oxide (NO) synthase alters the cerebral blood flow (CBF) response to α2-adrenergic stimulation during isoflurane anesthesia in dogs. In control animals (n = 6), CBF (microspheres), cerebral oxygen consumption (CMRO2), and electro- encephalograph (EEG) were measured after 1 h of isoflurane (1.4% end-tidal) and before and 5, 10, and 20 min after injection of an α2-adrenergic receptor agonist (dexmedetomidine 10 μg/kg, intravenous [IV] bolus). Dogs in a second group (n = 6) were treated similar to control animals except that an irreversible blocker of NO synthase, N(ω)-nitro-L-arginine methyl ester (L- NAME; 40 mg/kg, IV) was administered 1 h before induction of anesthesia. In control dogs, dexmedetomidine decreased CBF by 37% (P <0.05). Blood flow remained decreased for the 20 min observation period in all brain regions except cerebellum and caudate. In the L-NAME group, control CBF was 45% less than baseline flow in the control group (P <0.05) and dexmedetomidine further decreased CBF from 41 ± 7 mL · 100 g-1 · min-1 to 24 ± 2 mL · 100 g-1 · min-1 (P <0.05). There was no difference between groups in the percent of reduction of blood flow in any region after dexmedetomidine administration. Control CMRO2 was similar in the two groups and was unchanged by dexmedetomidine. These data demonstrate that L-NAME reduces CBF and that block of NO synthase does not affect α2-adrenergic-mediated decreases in CBF during isoflurane anesthesia.

AB - We assessed whether blocking nitric oxide (NO) synthase alters the cerebral blood flow (CBF) response to α2-adrenergic stimulation during isoflurane anesthesia in dogs. In control animals (n = 6), CBF (microspheres), cerebral oxygen consumption (CMRO2), and electro- encephalograph (EEG) were measured after 1 h of isoflurane (1.4% end-tidal) and before and 5, 10, and 20 min after injection of an α2-adrenergic receptor agonist (dexmedetomidine 10 μg/kg, intravenous [IV] bolus). Dogs in a second group (n = 6) were treated similar to control animals except that an irreversible blocker of NO synthase, N(ω)-nitro-L-arginine methyl ester (L- NAME; 40 mg/kg, IV) was administered 1 h before induction of anesthesia. In control dogs, dexmedetomidine decreased CBF by 37% (P <0.05). Blood flow remained decreased for the 20 min observation period in all brain regions except cerebellum and caudate. In the L-NAME group, control CBF was 45% less than baseline flow in the control group (P <0.05) and dexmedetomidine further decreased CBF from 41 ± 7 mL · 100 g-1 · min-1 to 24 ± 2 mL · 100 g-1 · min-1 (P <0.05). There was no difference between groups in the percent of reduction of blood flow in any region after dexmedetomidine administration. Control CMRO2 was similar in the two groups and was unchanged by dexmedetomidine. These data demonstrate that L-NAME reduces CBF and that block of NO synthase does not affect α2-adrenergic-mediated decreases in CBF during isoflurane anesthesia.

UR - http://www.scopus.com/inward/record.url?scp=0028153666&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028153666&partnerID=8YFLogxK

M3 - Article

VL - 78

SP - 67

EP - 72

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -